Search for other papers by Myrian Velasco in
Google Scholar
PubMed
Search for other papers by Rosa Isela Ortiz-Huidobro in
Google Scholar
PubMed
Search for other papers by Carlos Larqué in
Google Scholar
PubMed
Search for other papers by Yuriko Itzel Sánchez-Zamora in
Google Scholar
PubMed
Search for other papers by José Romo-Yáñez in
Google Scholar
PubMed
Search for other papers by Marcia Hiriart in
Google Scholar
PubMed
more abundant than in men, irrespective of ethnicity, BMI, or age ( 25 ). These differences are related to an estrogenic effect ( 26 ). Premenopausal women tend to accrue more subcutaneous gluteal-femoral fat; where subcutaneous adipocytes have more TG
Search for other papers by Lina S Silva-Bermudez in
Google Scholar
PubMed
Search for other papers by Freddy J K Toloza in
Google Scholar
PubMed
Search for other papers by Maria C Perez-Matos in
Google Scholar
PubMed
Search for other papers by Russell J de Souza in
Google Scholar
PubMed
Search for other papers by Laura Banfield in
Google Scholar
PubMed
Search for other papers by Andrea Vargas-Villanueva in
Google Scholar
PubMed
Search for other papers by Carlos O Mendivil in
Google Scholar
PubMed
Introduction Four of every five reproductive-age women in the world have used oral contraceptives (OC) ( 1 ). Most OC combine one estrogen with one progestin so there are multiple possible combinations and dosing schemes. Although OC are
Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, People’s Republic of China
Search for other papers by Lijuan Yuan in
Google Scholar
PubMed
Search for other papers by Xihui Chen in
Google Scholar
PubMed
Search for other papers by Ziyu Liu in
Google Scholar
PubMed
Search for other papers by Dan Wu in
Google Scholar
PubMed
Search for other papers by Jianguo Lu in
Google Scholar
PubMed
Search for other papers by Guoqiang Bao in
Google Scholar
PubMed
Search for other papers by Sijia Zhang in
Google Scholar
PubMed
Search for other papers by Lifeng Wang in
Google Scholar
PubMed
Search for other papers by Yuanming Wu in
Google Scholar
PubMed
females may lead to higher local concentration of both PGE2 and PGF2α, which would inevitably disturb the PG regulation of the menstrual cycle ( 48 ). The uncontrolled levels of luteotropic PGE2 would maintain high levels of luteal origin estrogen and
Search for other papers by T L C Wolters in
Google Scholar
PubMed
Division of Vascular Medicine, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
Search for other papers by C D C C van der Heijden in
Google Scholar
PubMed
Search for other papers by N van Leeuwen in
Google Scholar
PubMed
Search for other papers by B T P Hijmans-Kersten in
Google Scholar
PubMed
Search for other papers by M G Netea in
Google Scholar
PubMed
Search for other papers by J W A Smit in
Google Scholar
PubMed
Research Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK
Search for other papers by D H J Thijssen in
Google Scholar
PubMed
Search for other papers by A R M M Hermus in
Google Scholar
PubMed
Search for other papers by N P Riksen in
Google Scholar
PubMed
Search for other papers by R T Netea-Maier in
Google Scholar
PubMed
.08 Hormonal deficiency 2 30 <0.001 Estrogen depletion 13 25 0.56 Hypothyroidism 2 18 0.01 Hypogonadism 0 20 <0.001 Hypocortisolism 0 15 <0.001 GH deficiency 0 2 0.53 Diabetes
Search for other papers by Yunting Lin in
Google Scholar
PubMed
Search for other papers by Endi Song in
Google Scholar
PubMed
Search for other papers by Han Jin in
Google Scholar
PubMed
Search for other papers by Yong Jin in
Google Scholar
PubMed
body of evidence suggested that estrogen replacement therapy has not been successful in reducing the incidence of CVD-related diseases in postmenopausal women ( 23 ). Some studies have indicated that FSH or LH could potentially contribute to CVD events
Search for other papers by Kaisu Luiro in
Google Scholar
PubMed
Search for other papers by Kristiina Aittomäki in
Google Scholar
PubMed
Search for other papers by Pekka Jousilahti in
Google Scholar
PubMed
Department of Obstetrics and Gynecology, University of Oulu and Oulu University Hospital, Medical Research Center, PEDEGO Research Unit, Oulu, Finland
Search for other papers by Juha S Tapanainen in
Google Scholar
PubMed
receptor mutation was discovered 20 years ago, but its long-term effects on health and morbidity, and the effect of estrogen hormone therapy (HT) have not been thoroughly investigated. There is evidence that some of the adverse events related to POI may be
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1141, DHU PROTECT, Paris, France
Search for other papers by Juliane Léger in
Google Scholar
PubMed
Search for other papers by Anne Fjellestad-Paulsen in
Google Scholar
PubMed
Search for other papers by Anne Bargiacchi in
Google Scholar
PubMed
Search for other papers by Catherine Doyen in
Google Scholar
PubMed
Search for other papers by Emmanuel Ecosse in
Google Scholar
PubMed
Université Paris Diderot, Sorbonne Paris Cité, Paris, France
Institut National de la Santé et de la Recherche Médicale (INSERM), Unité 1141, DHU PROTECT, Paris, France
Search for other papers by Jean-Claude Carel in
Google Scholar
PubMed
Search for other papers by Marie-France Le Heuzey in
Google Scholar
PubMed
treatment, at the ages of 15.8 and 16.5 years, respectively, with menarche occurring under estroprogesterone treatment; ***Patient 1 refused estrogen treatment. Individual changes in pubertal stage among baseline, the end of hGH treatment and the
Search for other papers by Henrik H Thomsen in
Google Scholar
PubMed
Search for other papers by Holger J Møller in
Google Scholar
PubMed
Search for other papers by Christian Trolle in
Google Scholar
PubMed
Search for other papers by Kristian A Groth in
Google Scholar
PubMed
Search for other papers by Anne Skakkebæk in
Google Scholar
PubMed
Search for other papers by Anders Bojesen in
Google Scholar
PubMed
Search for other papers by Christian Høst in
Google Scholar
PubMed
Medical Research Laboratories, Departments of Clinical Biochemistry, Molecular Medicine, Department of Clinical Genetics, Department of Endocrinology and Internal Medicine, Clinical Institute, Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark
Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
sex hormones, i.e. estrogen–progestin and testosterone, would impact circulating levels of sCD163. To that end we studied samples drawn from one study with KS, one with TS (24, 25, 26) , and one experimental study of acute male hypogonadism. We
Search for other papers by Willem de Ronde in
Google Scholar
PubMed
Search for other papers by Diederik L Smit in
Google Scholar
PubMed
phase is accompanied by a cutting cycle of anabolic steroids. Since estrogens are assumed to promote s.c. fat apposition, androgens in the cutting cycle should not be prone to aromatization. Therefore, trenbolone, stanozolole and drostanolone are
Department of Developmental and Cell Biology, University of California, Irvine, California, USA
Search for other papers by Angelica Amorim Amato in
Google Scholar
PubMed
Search for other papers by Hailey Brit Wheeler in
Google Scholar
PubMed
Department of Pharmaceutical Sciences, University of California, Irvine, California, USA
Department of Biomedical Engineering, University of California, Irvine, California, USA
Search for other papers by Bruce Blumberg in
Google Scholar
PubMed
DOHaD ( 17 ). Endocrine-disrupting chemicals The endocrine system ultimately modulates function in tissues that regulate weight and metabolism. Endocrine hormones such as insulin, thyroid hormone, estrogens, and androgens are well known to